Journal of Sport and Exercise Physiology

Journal of Sport and Exercise Physiology

determine the effects of resistance training on serum levels of GLP-1, DPP-4 and insulin resistance in obese men

Document Type : original article

Authors
Asieh Abbassi-Daloii 1
Reza Shaghi 1
Mozhgan Ahmadi 2
Mohammad ali Kohanpour 3
1 Department of Physical Education and Sports Sciences, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran
2 Department of Physical Education and Sports Sciences, Yadegare Emam Branch,Shahre Ray, Islamic Azad University of Tehran, Iran
3 PHD student of biochemistry and sports metabolism, Department of Physical Education and Sports Sciences, Tehran Markaz Branch, Islamic Azad University, Tehran, Iran
10.48308/joeppa.2017.98862
Abstract
Objective: The aim of this study was to determine the effects of resistance training on serum levels of GLP-1, DPP-4 and insulin resistance in obese men. Methods: 20 obese men (age 29/76±2/01 years, height 1/79±0/07m, weight 108/24±5/69 kg, BMI 33/49±1/18kg/square meters) divided into resistance training and control groups. The resistance training consisted of 6 stations with 55-75% of one repetition maximum, 3 days a week for 8 weeks. Blood in two phases, before and after 8 weeks (48 hours after the last training session) was collected after 12 hours fasting. Data were analyzed with ANONA repeated measures at P≤0.05. Results: serum levels of GLP-1 training group compared with the group control significantly increased (P=0.027). Glucose and DPP-4 serum levels of training group were significantly decreased compared with the control group (P = 0.019 and P = 0.003). But in training group did not change insulin resistance compared with the control group (P = 0.49). Conclusion: probably Protocol of resistance training due to in a significant increase in GLP-1 and significantly reduced in DPP-4 and these changes is Accompanied with reducing appetite and the regulation of glucose metabolism in obese men, but probably either had no significant effect on insulin resistance or more time of resistance training requires to see a significant difference in the parameter.
Keywords
Insulin resistance
resistance exercise
glucagon
like peptide
1
dipeptidyl peptidase
4
obesity
  1. Coskun O, Ocakci A, Bayraktaroglu T, Kanter M. (2004). Exercise training prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Tohoku journal of experimental medicine; 203(3): 145-54.
  2. Crampes F, Marion-Latard F, Zakaroff- Girard A, Glisezinski I, Harant I, Thalamas C, et al. (2003). Effects of a longitudinal training program on responses to exercise in overweight men. Obesity research; 11(2):247-56.
  3. Shin-ya Ueda, Hidehiro Nakahara and Tadayoshi Miyamoto. (2013). Effects of exercise on glucagon like peptide-1 (GLP-1). J Phys Fitness Sports Med, 2(2): 221-224.
  4. Gordon BA, Benson AC, Bird SR, Fraser SF. (2009). Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract; 83: 157-175.
  5. Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. (2011). Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol; 10: 1-15.
  6. Näslund E and Hellström PM. (2007). Appetite signaling: from gut peptides and enteric nerves to brain. Physiol Behav 92: 256-262.
  7. Barrera JG, Sandoval DA, D’Alessio DA and Seeley RJ. (2011). GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 7: 507-516.
  8. Knop FK, Vilsboll T, Holst JJ. (2009). Incretin-based therapy of type 2 diabetes mellitus. Current protein & peptide science; 10(1):46.
  9. Brown J, Dryburgh J, Ross S, Dupre J. (1975). Identification and actions of gastric inhibitory polypeptide. Recent progress in hormone research; 31:487.
  10. Amori RE, Lau J, Pittas AG. (2007). Efficacy and safety of incretin therapy in type 2 diabetes. JAMA: the journal of the American Medical Association; 298(2):194-206.
  11. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. (2002). Gastric inhibitory polypeptide: the neglected incretin revisited. Regulatory peptides; 107(1-3):1.
  12. Inagaki N, Seino Y, Takeda J, Yano H, Yamada Y, Bell GI, et al. (1989). Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene .Molecular Endocrinology; 3(6):1014-21.
  13. Kreymann B, Ghatei M, Williams G, Bloom S. (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. The Lancet; 330(8571):1300-4.
  14. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, et al. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical Endocrinology & Metabolism; 87(3):1239-46.
  15. Gutzwiller J, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. (1999). Glucagon-like peptide-1: a potent regulator of food intake in humans; 44(1):81-6.
  16. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, et al. (2011). Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to themetabolic syndrome. Diabetes; 60:1917–25.
  17. Raschke S, Eckardt K, Bjorklund-Holven K, Jensen J, Eckel J. (2013). Identification andvalidation of novel contraction-regulated myokines released from primaryhuman skeletal muscle cells. PLoS.24, 45-9.
  18. Drucker DJ (2007). Dipeptidyl peptidase-4 inhibition and the treatment of type2 diabetes: preclinical biology and mechanisms of action. Diabetes Care; 30:1335–43.
  19. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, et al. (2003). Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl AcadSci U S A; 100:6825–30.
  20. Howe SM, Hand TM, Manore MM. (2014). Exercise-Trained Men and Women: Role of Exercise and Diet on Appetite and Energy Intake. Nutrients. 10; 6(11):4935-4960.
  21. Martins C, Kulseng B, King NA, Holst JJ and Blundell JE. (2010). the effects of exercise-induced weight loss on appetite- related peptides and motivation to eat. J Clin Endocrinol Metab 95: 1609-1616.
  22. Reinehr T, Roth CL, Enriori P, Masur K. (2010). Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: relationships to peptide YY, pancreatic peptide, and insulin sensitivity. J Pediatr Endocrinol Metab, 23:101–8.
  23. Huda MS, Wilding JP and Pinkney JH. (2006). Gut peptides and the regulation of appetite. Obes Rev 7: 163-182.
  24. Chanoine JP, Mackelvie KJ, Barr SI, Wong AC, Meneilly GS and Elahi DH. (2008). GLP-1 and appetite responses to a meal in lean and overweight adolescents following exercise. Obesity (Silver Spring) 16: 202-204.
  25. Kadoglou N, Vrabas I, Kapelouzou A, Angelopoulou N. (2012). The association of physical activity with novel adipokines in patients with type 2 diabete. European Journal of Internal Medicine. 23: 137-142.
  26. Tang- Christenen M, Vrang N, Larsen PJ. (2001). Glucagons-like peptide containing pathways in the regulation of feeding behavior. Int J Obes Relat Metab Disord; 5: 42-7.
  27. Schick RR, Zimmermann JP, Vorm Wald T. (2002). Glucagons- like peptide-1 (7-36)-amide acts as lateral and medial hypothalamic sites to suppress feeding in rats. Am J Physiol Integr Comp Physiol; 284(6):R1427-35
  28. Howe SM, Hand TM, Manore MM. (2014). Exercise-Trained Men and Women: Role of Exercise and Diet on Appetite and Energy Intake. Nutrients. 10; 6(11):4935-4960.
  29. Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al (2011). Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 17: 1481-1489.
  30. Frosig C, Rose AJ, Treebak JT, Kiens B, Richter EA, Wojtaszewski JF.(2007). Effectsof endurance exercise training on insulin signaling in human skeletal mus-cle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160.Diabetes; 56:2093–102.
  31. Miyazaki M, Kato M, Tanaka K, Tanaka M, Kohjima M, Nakamura K, et al.(2012). Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fattyliver disease and its association with insulin resistance and glucose metabolism.Mol Med Rep; 5:729–33.
  32. Steven K, Malina B, Hazel H, Anny M, Sangeeta R. Kashyapc D, et al. (2013). Lower dipeptidyl peptidase-4 following exercise training plus weightloss is related to increased insulin sensitivity in adults with metabolicsyndrome. Peptides, 47; 142– 147.
  33. Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, et al. (2009). Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobi-lization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab; 94:846–52.
  34. Solomon TP, Haus JM, Marchetti CM, Stanley WC, Kirwan JP. (2009). Effects of exercisetraining and diet on lipid kinetics during free fatty acid-induced insulin resistance in older obese humans with impaired glucose tolerance. Am J PhysiolEndocrinol Metab; 297:E552–9.
  35. Samuel VT, Shulman GI. (2012). Mechanisms for insulin resistance: common threads and missing links. Cell; 148:852–71.
  36. Fadini GP, Avogaro A. (2011). Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.Vascul Pharmacol; 55:10–6.
  37. Fenicchia LM, Kanaley JA, Azevedo JL Jr, Miller CS, Weinstock RS, Carhart RL, et al. (2004). Influence of resistance exercise training on glucose control in women with type 2 diabetes. Metabolism 53:284 –289.
  38. Sunghwan S, In-Kyong J, Kim M, Yeon S, Sue S, Jae HK. (2011). Effects of Resistance Training and Aerobic Exercise on Insulin Sensitivity in Overweight Korean Adolescents: A Controlled Randomized Trial, Diabetes Metab J; 35(4): 418–426.
  39. Aminot-gilchrist DV, Anderson HD. (2004). Insulin resistance associated cardiovascular disease: potential benefits of CLA. American journal clinic nutration, 1159-1163.
  40. DeFronzo RA, Ferrannini F. (1991). Insulin resistance. A mul tifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. American Diabetes Association, 14:173-194.

  • Receive Date 28 February 2016
  • Revise Date 07 June 2023
  • Accept Date 31 December 2020
  • First Publish Date 31 December 2020
  • Publish Date 22 May 2017